Ken Griffin Mustang Bio, Inc. Transaction History

Citadel Advisors LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.35 - $0.72 $20,263 - $41,684	57,895 New	57,895 $21,000
Q2 2022 Aug 15, 2022	BUY	$0.58 - $1.13 $298,771 - $582,088	515,123 Added 1347.01%	553,365 $324,000
Q1 2022 May 16, 2022	SELL	$0.73 - $1.81 $75,720 - $187,745	-103,727 Reduced 73.06%	38,242 $39,000
Q4 2021 Feb 14, 2022	BUY	$1.66 - $2.64 $87,516 - $139,183	52,721 Added 59.07%	141,969 $235,000
Q3 2021 Nov 15, 2021	SELL	$2.58 - $3.36 $292,773 - $381,286	-113,478 Reduced 55.98%	89,248 $240,000
Q2 2021 Aug 16, 2021	BUY	$2.7 - $3.81 $341,541 - $481,953	126,497 Added 165.94%	202,726 $673,000
Q1 2021 May 17, 2021	SELL	$3.02 - $5.16 $213,453 - $364,708	-70,680 Reduced 48.11%	76,229 $253,000
Q4 2020 Feb 16, 2021	SELL	$2.66 - $4.18 $182,771 - $287,211	-68,711 Reduced 31.87%	146,909 $556,000
Q3 2020 Nov 16, 2020	BUY	$3.01 - $3.88 $542,636 - $699,478	180,278 Added 510.1%	215,620 $679,000
Q2 2020 Aug 14, 2020	SELL	$2.33 - $4.6 $5,179 - $10,225	-2,223 Reduced 5.92%	35,342 $112,000
Q1 2020 May 15, 2020	BUY	$1.91 - $4.52 $11,139 - $26,360	5,832 Added 18.38%	37,565 $101,000
Q4 2019 Feb 14, 2020	BUY	$2.57 - $4.08 $17,139 - $27,209	6,669 Added 26.61%	31,733 $129,000
Q3 2019 Nov 14, 2019	BUY	$2.74 - $4.65 $37,414 - $63,495	13,655 Added 119.69%	25,064 $81,000
Q2 2019 Aug 14, 2019	SELL	$2.66 - $6.28 $428 - $1,011	-161 Reduced 1.39%	11,409 $42,000
Q4 2018 Feb 14, 2019	SELL	$2.3 - $5.78 $9,427 - $23,692	-4,099 Reduced 26.16%	11,570 $34,000
Q3 2018 Nov 13, 2018	BUY	$5.71 - $7.58 $89,469 - $118,771	15,669 New	15,669 $0

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $27.4M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.